drugset
Drugs / KIT2014
last change 4 days ago re-read 3 minutes ago

KIT2014

Developed for
chronic obstructive pulmonary disease
Investigated by
Avance Clinical Pty Ltd. · Kither Biotech Srl

Trials 2

today NCT07668518 · Ph 1/2 NCT06659757 · Ph 1
202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06659757 Oct 2024 → Jul 2025 cystic fibrosis Kither Biotech Srl Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT07668518 Jul 2026 → Mar 2027 expected chronic obstructive pulmonary disease Kither Biotech Srl Not yet recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2026-06-19 Kither Biotech Srl Results Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases kitherbiotech.com ↗
The study results demonstrate KIT2014’s favourable safety and tolerability profile.
2022-03-31 Kither Biotech Srl Results Kither Biotech announces publication of new data in Science Translational Medicine kitherbiotech.com ↗
KIT2014 demonstrated a triple mechanism of action in reversing disease pathogenesis: enhancing functionality of CFTR channels and reducing bronchoconstriction and inflammation

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as KIT2014 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07668518 ↗
1

NCT06659757 ↗
Route Inhaled “administered by inhalation with a nebuliser” NCT06659757 ↗